Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 125,612,680
  • Shares Outstanding, K 729,670
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.36
  • Price/Sales 5.58
  • Price/Cash Flow 12.02
  • Price/Book 4.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
170.53 +0.95%
on 07/27/17
182.60 -5.72%
on 07/25/17
+1.30 (+0.76%)
since 06/27/17
3-Month
152.16 +13.14%
on 05/23/17
182.60 -5.72%
on 07/25/17
+9.43 (+5.80%)
since 04/27/17
52-Week
133.64 +28.82%
on 11/04/16
184.21 -6.55%
on 03/15/17
+1.47 (+0.86%)
since 07/27/16

Most Recent Stories

More News
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's supplemental Biologics License Application (sBLA) for Repatha® (evolocumab),...

AMGN : 172.15 (-2.13%)
Company News for July 27, 2017

Companies in the news are: AMD,ANTM,KO,AMGN

KO : 46.12 (+0.83%)
AMD : 14.12 (-4.34%)
ANTM : 183.52 (-0.79%)
AMGN : 172.15 (-2.13%)
Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK

Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.

MRK : 63.69 (+3.06%)
LLY : 83.02 (+1.44%)
VRTX : 156.19 (-4.42%)
ABBV : 71.73 (-1.18%)
AMGN : 172.15 (-2.13%)
GSK : 40.75 (-0.24%)
BIIB : 287.95 (-2.59%)
Today's Research Reports on Stocks to Watch: Amgen and United States Steel Corporation

NEW YORK, NY / ACCESSWIRE / July 27, 2017 / Amgen shares fell into the red on Wednesday despite beating in both revenue and earnings in its second quarter report. Traders were disappointed over analysts...

X : 25.00 (-4.58%)
AMGN : 172.15 (-2.13%)
Asian shares gain on strong earnings, dovish Fed policy

TOKYO (AP) — Asian shares were mostly higher Thursday, supported by strong corporate earnings and the Federal Reserve's decision to pause its slow-moving campaign to raise interest rates.

VZ : 47.81 (+7.68%)
T : 39.41 (+3.63%)
AMD : 14.12 (-4.34%)
AMGN : 172.15 (-2.13%)
Amgen Inc Set to Possibly Rebound After Yesterday's Selloff of 2.79%

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $175.20 to a high of $178.85. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $178.66...

AMGN : 172.15 (-2.13%)
Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

CELG : 134.15 (-2.61%)
NVS : 84.97 (+0.14%)
AMGN : 172.15 (-2.13%)
SNY : 48.09 (+0.15%)
Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

IRWD : 16.65 (-2.63%)
MDCO : 37.95 (-0.99%)
INCY : 132.72 (-3.26%)
GILD : 74.96 (+1.04%)
AMGN : 172.15 (-2.13%)
BIIB : 287.95 (-2.59%)
NKTR : 22.61 (-2.21%)
Amgen Reports Second Quarter 2017 Financial Results

Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2017. Key results include:

AMGN : 172.15 (-2.13%)
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

JNJ : 130.83 (-0.09%)
ABBV : 71.73 (-1.18%)
AMGN : 172.15 (-2.13%)
BIIB : 287.95 (-2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 177.67
1st Resistance Point 174.91
Last Price 172.15
1st Support Level 169.96
2nd Support Level 167.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.